Aberrant DLX gene expression has been shown for both DLX1 and DLX2 in T-ALL, AML and myelodysplastic syndrome (MDS) patients, showing divergent regulation in the malignant context [18,22]. The gene discussed is DLX2; the disease is myelodysplastic syndrome.